Jump to content

IXICO

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 21:08, 15 March 2022 (Add: title. Changed bare reference to CS1/2. | Use this bot. Report bugs. | Suggested by BrownHairedGirl | Linked from User:BrownHairedGirl/Articles_with_bare_links | #UCB_webform_linked 772/2846). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

IXICO
Company typePublic limited company
LSE:IXI
IndustryData analytics for clinical research
Founded2004
FoundersProfessors Derek Hill, Daniel Rueckert, David Hawkes and Jo Hajnal
Headquarters
London
,
United Kingdom
Area served
Worldwide
Key people
Charles Spicer (Chairman)
Giulio Cerroni (CEO)
Websitehttps://ixico.com/

IXICO plc is a UK clinical research firm that provides neuroimaging and digital biomarker analytics to biopharmaceutical firms conducting clinical trials into neurological diseases such as Alzheimer’s disease (AD) and Huntington’s disease (HD).

Company history

IXICO was incorporated in 2004[1] as a spin-out from three London academic institutions: Imperial College London, University College London and King's College London.[2] The initial 3-year research project was called ‘Information eXtraction from Images’ (hence the IXI name), and funded by the UK e-science core and other industry partners.[3]

In October 2013, IXICO entered the Alternative Investment Market (AIM) of the London Stock Exchange through a reverse takeover of defunct pharmaceutical drug company Phytopharm.[4]

Phytopharm

Phytopharm was a British pharmaceutical company, incorporated on 28 November 1995. Briefly known as Lawnhale, it changed its name to Phytopharm in March 1996[5] and listed on the London Stock Exchange on 25 April of the same year (LSE:PYM).[6] It announced plans for a secondary listing on NASDAQ in 2004 (NASDAQ:PHYOF).[7] By 2012, the Phytopharm group consisted of a parent company, Phytopharm plc, a wholly owned trading subsidiary, Phytotech Limited, and a dormant subsidiary, Phytodevelopments Limited.[8]

Amongst other activity, Phytopharm raised funds for research into treatment of Parkinson’s disease (PD) from sources including the Michael J Fox Foundation,[9] but the company collapsed in 2013 following the failure of its main PD drug (Cogane) during clinical trials.[10] Its shares were suspended from trading on 20 May 2013.[11][12]

References

  1. ^ Chesters, Laura (24 September 2013). "Independent". Retrieved 30 November 2018.
  2. ^ Nair, Praseeda (8 August 2006). "growthbusiness.co.uk". Retrieved 30 November 2018.
  3. ^ "What is IXI?". www0.cs.ucl.ac.uk. Retrieved 30 November 2018.
  4. ^ "Phytopharm plc to be renamed IXICO plc on admission - London Stock Exchange". www.londonstockexchange.com. Retrieved 30 November 2018.
  5. ^ "IXICO PLC - Overview (free company information from Companies House)". beta.companieshouse.gov.uk. Retrieved 4 December 2018.
  6. ^ "Resources".
  7. ^ "Phytopharm turns to Nasdaq in search for US investors". The Independent. Retrieved 4 December 2018.
  8. ^ "Phytopharm PLC Preliminary Results". ADVFN. Retrieved 4 December 2018.
  9. ^ "Phytopharm turns to Nasdaq in search for US investors". The Independent. Retrieved 4 December 2018.
  10. ^ "Cogane for Parkinson's Shows No Benefit over Placebo in Clinical Trial". The Michael J. Fox Foundation for Parkinson's Research | Parkinson's Disease. Retrieved 4 December 2018.
  11. ^ "Phytopharm (PYM) Share Price". ADVFN. Retrieved 4 December 2018.
  12. ^ "Phytopharm suspends shares pending acquisition | Business Weekly | Technology News | Business news | Cambridge and the East of England". www.businessweekly.co.uk. Retrieved 4 December 2018.
Retrieved from "https://en.wikipedia.org/w/index.php?title=IXICO&oldid=1077345670"